Rainbow Coral Corp. (OTCBB: RBCC) is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC’s joint venture partner, Nano3D Biosciences (n3D).
Many experts believe that 3D bioprinting equipment like the BiO Assay is poised to solve the complex problems faced by biotech firms by giving them the opportunity to test drugs on functional human tissues in order to better understand and predict a drug’s effect on the body. The BiO Assay uses magnetism to assemble cells in 3D and into conditions that closely mimic those found in vivo, giving drug makers functional preclinical human tissues far more useful than any animal or test tube models.
And with better testing results will come bigger profits for drug companies, says RBCC CEO Kimberly Palmer. “Research has been hampered for too long by traditional cell culture models that have proven to be poor predictors of drug efficacy and toxicity in humans,” Palmer said. “The BiO Assay has been engineered to reduce costs and improve results across a broad spectrum of tests and assays. It provides a renewable and easy-to-use source of lifelike cell cultures that will change the way research is conducted across the globe.”
The BiO Assay represents a revolution in pharmaceutical research, offering better and faster results than have previously been possible.
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.